Published: August 2021 | Report Code: LS12237 | Available Format: PDF | Pages: 300
The global professional acne treatment market generated $6,298.9 million revenue in 2020, and it is expected to grow at a CAGR of 7.6% during 2020–2030. This growth is attributed to the rising incidence of acne, growing disposable income in developed and developing countries, rising healthcare spending, and surging number of research programs.
During the COVID-19 pandemic, lockdowns have affected the whole world. Due to this, there has been a negative impact on the product sales and supply chains of numerous sectors, particularly during the first two quarters of the year 2020. This has adversely affected the trade of acne treatment products due to the reduced demand, constraints in the handling and transportation of goods, and widespread financial distress. In addition, the COVID-19 situation forced thousands of companies to shut down their assembly and manufacturing plants temporarily, thus leading to decreased raw material and component supply for acne treatment product manufacturing, thereby resulting in reduced sales.
Inflammatory acne held the larger share in 2020 in the professional acne treatment market, based on acne type. This is majorly attributed to the immediate requirement for effective treatment because it is generally painful. Furthermore, the commonly available salicylic acid and benzoyl-peroxide-based over-the-counter (OTC) products are not fully effective on inflammatory acne. Therefore, branded and generic drugs are offered by major pharmaceutical companies, on prescription, for inflammatory acne.
The devices category is expected to witness the faster growth in the professional acne treatment market during the forecast period (2021–2030), based on treatment type. This will primarily be due to the rising adoption of laser- and light-based acne treatments, mainly in developed economies, owing to the side-effects of drugs.
The dermatologists category is expected to lead the professional acne treatment market during the forecast period, based on professional type. This is attributed to the increasing number of skilled dermatologists treating skin diseases, including acne. Additionally, patients prefer dermatologists because of their extensive expertise and experience in dealing with the problem.
North America dominated the market during the historical period (2014–2020) due to the rising incidence of acne, increasing awareness on newly developed drugs, large pipeline of drugs, and high per capita income in the region. Moreover, the region is marked by the presence of prominent dermatology drug manufacturers, such as Johnson & Johnson, Bausch Health Companies Inc., and Pfizer Inc., who provide numerous classes of drugs to the North American population.
Many pharmaceutical companies are launching novel products, which have become a major trend in the market for professional acne treatment products. For instance, in August 2020, Cassiopea SpA received the U.S. Food and Drug Administration (FDA) approval for Winlevi, a clascoterone-based cream designed for the treatment of acne in patients 12 years and older. Moreover, AnnJi Pharmaceutical Co. Ltd. is engaged in the development of AJ101, which is a topical cream formulation for the treatment of acne vulgaris. The active ingredient in AJ101 is a novel androgen receptor degradation enhancer, which effectively decreases the level of activity of the androgen receptor, mediated by the ubiquitin–proteasome system through the activation of the Nrf1 pathway.
People are focusing on enhancing their appearance by actively investing in a comprehensive skincare regimen for acne, scars, and other skin problems. There are various treatment options available, such as topical therapies, systemic agents, physical modalities, lasers, and photodynamic therapy. Moreover, to permanently minimize the occurrence of acne, clinicians suggest the use of combination therapies, such as those involving a topical antibiotic and a retinoid, which, in turn, is having a positive influence on the market.
The adolescent and young adult populations are highly prone to acne, which leads to a high volume of dermatologist and cosmetician consultations. Acne vulgaris is one of the most-prevalent dermatological disorders, affecting majority of the world's population at some point during their lives. For instance, according to the American Academy of Dermatology (AAD), acne affects 50 million people annually in the U.S., while as per the Global Health Data Exchange (GHDX), the prevalence of acne was 2.3 million people in Italy, 1.8 million in Spain, and 3.7 million in Germany in 2019. This strengthens the use of curative drugs and devices worldwide, thereby boosting the market revenue.
|Base Year (2020) Market Size||$6,298.9 Million|
|Market Size Forecast in 2030||$13,124.5 Million|
|Forecast Period CAGR||7.6%|
|Report Coverage||Market Trends, Drivers, and Restraints, Revenue Estimation and Forecast, Segmentation Analysis, Country Breakdown, Impact of COVID-19, Companies’ Strategic Developments, Company Share Analysis, Company Profiling|
|Market Size by Segments||By Acne Type, By Treatment Type, By Professional Type, By Region|
|Market Size of Geographies||U.S., Canada, Germany, Italy, Spain, Netherlands, France, Belgium, Austria, Sweden, Denmark, Japan, China, India, South Korea, Australia,|
|Secondary Sources and References (Partial List)||American Academy of Dermatology, American Academy of Family Physicians, American Acne and Rosacea Society, American Dermatological Association, Asian Academy of Dermatology and Venerology, Asian Dermatological Association, British Association of Dermatologists, Centers for Disease Control and Prevention, Chinese Society of Dermatology, European Academy of Dermatology and Venereology, European Medicines Agency, European Societies of Dermatology, Indian Association of Dermatologists, Venereologists and Leprologists, International Association for Medical Assistance to Travellers|
The professional acne treatment market is fragmented in nature with the presence of several key players. Some of the major players in the industry are Galderma SA, Johnson & Johnson, Bausch Health Companies Inc., Pfizer Inc., CHEPLAPHARM Arzneimittel GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Bayer AG, Perrigo Company plc, Almirall S.A., Lumenis Ltd., Candela Corporation, Alma Lasers Ltd., Cutera Inc., Sciton Inc., EL.EN. S.p.a., Fotona d.o.o., Venus Concept Inc., Erchonia Corporation, and InMode Ltd.
In recent years, players in the global professional acne treatment market have been involved in product launches in order to attain a significant position. For instance:
The global professional acne treatment market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.
Based on Acne Type
Based on Treatment Type
Based on Professional Type
The market for professional acne treatment products will value $13,124.5 million in 2030.
The higher revenue in the professional acne treatment industry is attributed to dermatologists.
APAC will witness the fastest growth in the market for professional acne treatment drugs and devices.
The professional acne treatment industry competitive landscape is fragmented.
For business growth, players in the market for professional acne treatment products are seeking regulatory product approvals and engaging in mergers and acquisitions.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws